Molecular diagnostics of non-small cell lung cancer: New markers and technologies;Molekulardiagnostik des nichtkleinzelligen Lungenkarzinoms: Neue Marker und Technologien

Pathologe

Volumn 36, Issue 2, 2015, Pages 154-163

  Warth, A ^a,c   Endris, V ^a   Kriegsmann, M ^a   Stenzinger, A ^a   Penzel, R ^a   Pfarr, N ^a   Weichert, W ^a,b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b C o Institut für Medizinische Biometrie und Informatik   (Germany)

^c Translationales Lungenforschungszentrum Heidelberg (TLRCH)   (Germany)

Author keywords

Immunomodulatory drugs; Lung cancer; Massively parallel sequencing; Molecular diagnostics; Sequential testing

Indexed keywords

GENETIC MARKER;

CARCINOMA, NON-SMALL-CELL LUNG; DRUG DELIVERY SYSTEM; GENETIC MARKER; GENETICS; HUMAN; IMMUNOTHERAPY; LUNG; MOLECULAR DIAGNOSIS; PATHOLOGY; PERSONALIZED MEDICINE; PROGNOSIS;

CARCINOMA, NON-SMALL-CELL LUNG; DRUG DELIVERY SYSTEMS; GENETIC MARKERS; HUMANS; IMMUNOTHERAPY; LUNG; MOLECULAR DIAGNOSTIC TECHNIQUES; PRECISION MEDICINE; PROGNOSIS;

EID: 84937759622     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00292-015-0004-4     Document Type: Article

References (60)

1. Anonymous (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489:519–525
2. Anonymous (2013) A genomics-based classification of human lung tumors. Sci Transl Med 5:209ra153
3. Beau-Faller M, Gaub MP, Schneider A et al (2003) Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer patients. Int J Cancer 105:361–370
4. Bepler G, Williams C, Schell MJ et al (2013) Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 31:2404–2412
5. Besse B, Olaussen KA, Soria JC (2013) ERCC1 and RRM1: Ready for Prime Time? J Clin Oncol 31:1050–1060
6. Bos M, Gardizi M, Schildhaus HU et al (2013) Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS 1 gene rearrangement after treatment with crizotinib. Lung Cancer 81:142–143
7. Camidge DR, Bang YJ, Kwak EL et al (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 13:1011–1019
8. Casadonte R, Kriegsmann M, Zweynert F et al (2014) Imaging mass spectrometry to discriminate breast from pancreatic cancer metastasis in formalin-fixed paraffin-embedded tissues. Proteomics 14:956–964
9. Cortot AB, Janne PA (2014) Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas. Eur Respir Rev 23:356–366
10. Endris V, Penzel R, Warth A et al (2013) Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing. J Mol Diagn 15:765–775
11. Fernandez-Cuesta L, Peifer M, Lu X et al (2014) Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nat Commun 5:3518
12. Findeisen P, Neumaier M (2009) Mass spectrometry-based clinical proteomics profiling: current status and future directions. Expert Rev Proteomics 6:457–459
13. Fleischhacker M, Schmidt B (2007) Circulating nucleic acids (CNAs) and cancer – a survey. Biochim Biophys Acta 1775:181–232
14. Fournie GJ, Courtin JP, Laval F et al (1995) Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours. Cancer Lett 91:221–227
15. Friboulet L, Olaussen KA, Pignon JP et al (2013) ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 368:1101–1110
16. Gautschi O, Bigosch C, Huegli B et al (2004) Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol 22:4157–4164
17. Groschel A, Warth A, Reinmuth N (2013) Crizotinib – molecular therapy for lung cancer. Pneumologie 67:205–208
18. Herpel E, Schnabel PA, Steins M et al (2012) Assessment of thymidylate synthase expression in biopsy specimens and corresponding resection specimens of non-small-cell lung cancer. Histopathology 61:465–472
19. Herth FJ, Bubendorf L, Gutz S et al (2013) Diagnostic and predictive analyses of cytological specimens of non-small cell lung cancer: strategies and challenges. Pneumologie 67:198–204
20. Hirsch FR, Janne PA, Eberhardt WE et al (2013) Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol 8:373–384
21. Imielinski M, Berger AH, Hammerman PS et al (2012) Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150:1107–1120
22. Jahr S, Hentze H, Englisch S et al (2001) DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61:1659–1665
23. Jamal-Hanjani M, Hackshaw A, Ngai Y et al (2014) Tracking genomic cancer evolution for precision medicine: the lung TRACERx study. PLoS Biol 12:e1001906
24. Kim Y, Hammerman PS, Kim J et al (2014) Integrative and comparative genomic analysis of lung squamous cell carcinomas in East asian patients. J Clin Oncol 32:121–128
25. Kimura H, Suminoe M, Kasahara K et al (2007) Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer 97:778–784
26. Kossakowski CA, Morresi-Hauf A, Schnabel PA et al (2014) Preparation of cell blocks for lung cancer diagnosis and prediction: protocol and experience of a high-volume center. Respiration 87:432–438
27. Kris MG, Johnson BE, Berry LD et al (2014) Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311:1998–2006
28. Lederlin M, Puderbach M, Muley T et al (2013) Correlation of radio- and histomorphological pattern of pulmonary adenocarcinoma. Eur Respir J 41:943–951
29. Leon SA, Shapiro B, Sklaroff DM et al (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37:646–650
30. M VL, Warth A, Penzel R et al (2013) Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing. Lung cancer 81:200–206
31. Mandel P (1940) Les acides nucleiques du plasma sanguine chez l’homme. C R Acad Sci Paris 142:241–253
32. Muley TR, Sianidou M, Thomas M et al (2014) Comparison of two ERCC1 antibodies as prognostic and predictive biomarkers for early non-small cell lung cancer. Anticancer Res 34:3707–3713
33. Ohashi K, Maruvka YE, Michor F et al (2013) Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol 31:1070–1080
34. Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983–991
35. Pantel K, Alix-Panabieres C (2013) Real-time liquid biopsy in cancer patients: fact or fiction? Cancer Res 73:6384–6388
36. Peifer M, Fernandez-Cuesta L, Sos ML et al (2012) Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 44:1104–1110
37. Reynolds C, Obasaju C, Schell MJ et al (2009) Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 27:5808–5815
38. Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–246
39. Roth JA, Carlson JJ (2011) Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer 12:393–401
40. Scagliotti GV, Parikh P, Von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543–3551
41. Shapiro B, Chakrabarty M, Cohn EM et al (1983) Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer 51:2116–2120
42. Shaw AT, Engelman JA (2013) ALK in lung cancer: past, present, and future. J Clin Oncol 31:1105–1111
43. Shaw AT, Ou SH, Bang YJ et al (2014) Crizotinib in ROS 1-rearranged non-small-cell lung cancer. N Engl J Med 371:1963–1971
44. Soda M, Choi YL, Enomoto M et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561–566
45. Sozzi G, Conte D, Mariani L et al (2001) Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 61:4675–4678
46. Stenzinger A, Penzel R, Endris V et al (2013) Molecular diagnostics in pathology. Dtsch Med Wochenschr 138:1061–1068
47. Stroun M, Maurice P, Vasioukhin V et al (2000) The origin and mechanism of circulating DNA. Ann N Y Acad Sci 906:161–168
48. Taniguchi K, Uchida J, Nishino K et al (2011) Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res 17:7808–7815
49. Travis WD, Brambilla E, Noguchi M et al (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244–285
50. Von Laffert M, Penzel R, Schirmacher P et al (2014) Multicenter ALK testing in non-small-cell lung cancer: results of a round robin test. J Thorac Oncol 81:200–206
51. Wang T, Chuan Pan C, Rui Yu J et al (2013) Association between TYMS expression and efficacy of pemetrexed-based chemotherapy in advanced non-small cell lung cancer: a meta-analysis. PloS One 8:e74284
52. Warth A, Endris V, Penzel R et al (2014) Molecular pathology of lung cancer: State of the art 2014. Pathologe 35:565–573
53. Warth A, Muley T, Dienemann H et al (2014) ROS 1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases. Histopathology 65:187–194
54. Warth A, Muley T, Herpel E et al (2012) Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies. Histopathology 61:1017–1025
55. Warth A, Muley T, Meister M et al (2012) The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 30:1438–1446
56. Warth A, Muley T, Meister M, Weichert W et al (2015) Preanalytics in lung cancer. Recent Results Cancer Res 199:71–84
57. Warth A, Penzel R, Brandt R et al (2012) Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies. Virchows Arch 460:407–414
58. Warth A, Penzel R, Lindenmaier H et al (2014) EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype. Eur Respir J 43:872–883
59. Warth A, Stenzinger A, Weichert W (2013) Novel morphological and molecular aspects of lung cancer. Pathologe 34:419–428
60. Weichert W, Warth A (2014) Early lung cancer with lepidic pattern: adenocarcinoma in situ, minimally invasive adenocarcinoma, and lepidic predominant adenocarcinoma. Curr Opin Pulm Med 20:309–316